Opinion

Video

Adverse Effect Management and the Role of Immunotherapy in NMIBC

Author(s):

Gordon A. Brown, DO,Siamak Daneshmand, MD

Experts on bladder cancer discusses strategies to minimize adverse effects and the role of immunotherapy in BCG-unresponsive NMIBC treatment paradigms.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
      Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
      Jason Hafron, MD, considers the future for AI in urology
      Jason Hafron, MD, considers the future for AI in urology
      Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
      Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
      Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
      Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      How recombinant BCG could ease strain of supply issues
      Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
      Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
      John Taylor, III, MD, on novel options in NMIBC
      John Taylor, III, MD, on novel options in NMIBC
      Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
      Suzanne B. Merrill, MD, FACS, on EAP program for recombinant BCG
      3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
      What a long-term study of patients undergoing RARC reveals about upstaging
      Sima Porten, MD, on the increased risk of bladder cancer among firefighters
      Sima Porten, MD, on the increased risk of bladder cancer among firefighters
      Related Content
      Close-up shot of microscope with metal lens at laboratory. | Image Credit: © kkolosov - stock.adobe.com
      April 2nd 2025

      The importance of federal funding in cancer research: A call to action

      Michael S. Cookson, MD, MMHC
      "We must lobby to maintain our current funding levels and push for increased support to continue driving progress in cancer care," says Michael S. Cookson, MD, MMHC, FACS.
      medical depiction of bladder cancer
      May 31st 2023

      Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

      Urology Times staff
      In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
      Investigational Combination Immunotherapy Treatment for High-Risk, Late-Stage Prostate Cancer Patients Available in Michigan
      March 31st 2025

      Investigational Combination Immunotherapy Treatment for High-Risk, Late-Stage Prostate Cancer Patients Available in Michigan

      Michigan Institute of Urology
      Michigan Institute of Urology is a clinical trial site for LEGION-100.
      Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease
      May 26th 2022

      Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

      Urology Times staff
      “We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.
      FDA approves durvalumab/chemo for muscle–invasive bladder cancer
      March 28th 2025

      FDA approves durvalumab/chemo for muscle–invasive bladder cancer

      Hannah Clarke
      The approval is supported by results from the phase 3 NIAGARA trial.
      RAG-01 elicits complete responses in NMIBC
      March 26th 2025

      RAG-01 elicits complete responses in NMIBC

      Hannah Clarke
      "The striking CR rates observed in these early cohorts are highly encouraging, particularly for BCG-unresponsive NMIBC patients who currently have limited treatment options," says Paul D. Anderson, MBBS, FRACS.
      © 2025 MJH Life Sciences

      All rights reserved.